ImmunoPrecise Antibodies Ltd.

Informe acción TSXV:IPA

Capitalización de mercado: CA$162.1m

This company listing is no longer active

This company may still be operating, however this listing is no longer active. Find out why through their latest events.

Salud financiera de hoja de balance de ImmunoPrecise Antibodies

Salud financiera controles de criterios 4/6

Información clave

0%

Ratio deuda-patrimonio

CA$0

Deuda

Ratio de cobertura de interesesn/a
EfectivoCA$19.24m
PatrimonioCA$66.24m
Total pasivoCA$13.70m
Activos totalesCA$79.94m

Actualizaciones recientes sobre salud financiera

Recent updates

We Think ImmunoPrecise Antibodies (CVE:IPA) Needs To Drive Business Growth Carefully

Oct 20
We Think ImmunoPrecise Antibodies (CVE:IPA) Needs To Drive Business Growth Carefully

Earnings Update: ImmunoPrecise Antibodies Ltd. (CVE:IPA) Just Reported And Analysts Are Boosting Their Estimates

Dec 23
Earnings Update: ImmunoPrecise Antibodies Ltd. (CVE:IPA) Just Reported And Analysts Are Boosting Their Estimates

Is ImmunoPrecise Antibodies (CVE:IPA) Using Debt In A Risky Way?

Nov 25
Is ImmunoPrecise Antibodies (CVE:IPA) Using Debt In A Risky Way?

Análisis de la situación financiera

Pasivos a corto plazo: IPA's short term assets (CA$27.1M) exceed its short term liabilities (CA$5.4M).

Pasivo a largo plazo: IPA's short term assets (CA$27.1M) exceed its long term liabilities (CA$8.3M).


Historial y análisis de deuda-patrimonio

Nivel de deuda: IPA is debt free.

Reducción de la deuda: IPA had no debt 5 years ago.


Hoja de balance


Análisis de cash runway

En el caso de las empresas que de media han sido deficitarias en el pasado, evaluamos si tienen al menos 1 año de cash runway.

Cash runway estable: IPA has less than a year of cash runway based on its current free cash flow.

Pronóstico de cash runway: IPA has less than a year of cash runway if free cash flow continues to reduce at historical rates of 36% each year


Descubre empresas con salud financiera